EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Prospective randomized comparative study of the effect of pemafibrate add‐on or double statin dose on small dense low‐density lipoprotein ‐cholesterol in patients with type 2 diabetes and hypertriglyceridemia on statin therapy

Tsutomu Hirano iD, Toshiyuki Hayashi, Hiroe Sugita, Atsuko Tamasawa, Satoshi Goto, Masako Tomoyasu, Takeshi Yamamoto, Makoto Ohara iD, Michishige Terasaki iD, Hideki Kushima, Yasuki Ito, Sho-Ichi Yamagishi und 1 weitere

Journal of Diabetes Investigation · 2023

DOI: 10.1111/jdi.14076 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Diabetes Investigation, 2023. Verfasst von Tsutomu Hirano und 12 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes Center, Ebina General Hospital, Ebina, Japan. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Diabetes Mellitus, Type 2, Hypertriglyceridemia. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Kowa Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims/Introduction Small dense low‐density lipoprotein (sdLDL) is a more potent atherogenic lipoprotein than LDL. As sdLDL‐cholesterol (C) levels are determined by triglyceride and LDL‐C levels, pemafibrate and statins can reduce sdLDL‐C levels. However, it remains unclear whether adding pemafibrate or increasing statin doses would more effectively reduce sdLDL‐C levels in patients receiving statin therapy. Materials and Methods A total of 97 patients with type 2 diabetes and hypertriglyceridemia who were treated with statins were randomly assigned to the pemafibrate 0.2 mg/day addition or statin dose doubled, and followed for 12 weeks. sdLDL‐C was measured by our established homogenous assay.

Results

The percentage and absolute reductions of sdLDL‐C levels were significantly greater in the pemafibrate add‐on group than the statin doubling group (−32.8 vs −8.1%; −16 vs −3 mg/dL, respectively). Triglyceride levels were reduced only in the pemafibrate add‐on group (−44%), and LDL‐C levels were reduced only in the statin doubling group (−8%), whereas levels of non‐high‐density lipoprotein‐C and apolipoprotein B were similarly decreased (7–9%) in both groups. The absolute reductions of sdLDL‐C levels were closely associated with decreased triglyceride, LDL‐C, non‐high‐density lipoprotein‐C and apolipoprotein B. In the subgroup analysis, the effect of pemafibrate add‐on on sdLDL‐C reductions was observed irrespective of baseline lipid parameters or statin type. No serious adverse effects were observed in both groups.

Conclusions

In patients with type 2 diabetes and hypertriglyceridemia, the addition of pemafibrate to a statin is superior to doubling a statin in reducing sdLDL‐C without increasing adverse effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hydroxymethylglutaryl-CoA Reductase InhibitorsDiabetes Mellitus, Type 2HypertriglyceridemiaHumansCholesterol, LDLProspective StudiesTriglyceridesLipoproteinsApolipoproteinsBenzoxazolesButyrates

Stichwörter der Autor:innen

PemafibratesSmall dense low-density lipoproteinType 2 diabetes

Substanzen

Hydroxymethylglutaryl-CoA Reductase InhibitorsCholesterol, LDLTriglyceridesLipoproteinsApolipoproteins(R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acidBenzoxazolesButyrates

Autor:innen und Institutionen

  • Diabetes Center, Ebina General Hospital, Ebina, Japan.
  • Division of Diabetes, Metabolism, and Endocrinology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
  • Yurakubashi Clinic, Tokyo, Japan.
  • Asoka Hospital, Tokyo, Japan.
  • Goto Iin, Nara, Japan.
  • Clinical Diagnostics Department, Denka Co., Ltd., Tokyo, Japan.

ORCID-Profile: Tsutomu Hirano, Makoto Ohara, Michishige Terasaki

Förderung

  • Kowa Company

Zitieren

APA

Hirano, T., Hayashi, T., Sugita, H., Tamasawa, A., Goto, S., Tomoyasu, M., Yamamoto, T., Ohara, M., Terasaki, M., Kushima, H., Ito, Y., Yamagishi, S. I., & Mori, Y. (2023). Prospective randomized comparative study of the effect of pemafibrate add‐on or double statin dose on small dense low‐density lipoprotein ‐cholesterol in patients with type 2 diabetes and hypertriglyceridemia on statin therapy. Journal of Diabetes Investigation. https://doi.org/10.1111/jdi.14076

Vancouver

Hirano T, Hayashi T, Sugita H, Tamasawa A, Goto S, Tomoyasu M, et al. Prospective randomized comparative study of the effect of pemafibrate add‐on or double statin dose on small dense low‐density lipoprotein ‐cholesterol in patients with type 2 diabetes and hypertriglyceridemia on statin therapy. Journal of Diabetes Investigation. 2023. doi:10.1111/jdi.14076

BibTeX
@article{Hirano2023,
  author = {Hirano, Tsutomu and Hayashi, Toshiyuki and Sugita, Hiroe and Tamasawa, Atsuko and Goto, Satoshi and Tomoyasu, Masako and Yamamoto, Takeshi and Ohara, Makoto and Terasaki, Michishige and Kushima, Hideki and Ito, Yasuki and Yamagishi, Sho-Ichi and Mori, Yusaku},
  title = {Prospective randomized comparative study of the effect of pemafibrate add‐on or double statin dose on small dense low‐density lipoprotein ‐cholesterol in patients with type 2 diabetes and hypertriglyceridemia on statin therapy},
  journal = {Journal of Diabetes Investigation},
  year = {2023},
  doi = {10.1111/jdi.14076}
}
Kostenlos starten →